Last reviewed · How we verify

Placebo to tocilizumab

Hoffmann-La Roche · FDA-approved active Small molecule Quality 5/100

Placebo to tocilizumab is a IL-6 receptor antagonist Small molecule drug developed by Hoffmann-La Roche. It is currently FDA-approved for Rheumatoid arthritis (moderate to severe), Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway.

Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway. Used for Rheumatoid arthritis (moderate to severe), Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

At a glance

Generic namePlacebo to tocilizumab
SponsorHoffmann-La Roche
Drug classIL-6 receptor antagonist
TargetIL-6 receptor (IL-6R)
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Tocilizumab binds to both soluble and membrane-bound IL-6 receptors, preventing IL-6 from activating immune cells and reducing systemic inflammation. This mechanism suppresses the production of inflammatory cytokines and acute phase reactants, making it effective in conditions driven by IL-6-mediated inflammation such as rheumatoid arthritis and cytokine release syndrome.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Placebo to tocilizumab

What is Placebo to tocilizumab?

Placebo to tocilizumab is a IL-6 receptor antagonist drug developed by Hoffmann-La Roche, indicated for Rheumatoid arthritis (moderate to severe), Giant cell arteritis, Polyarticular juvenile idiopathic arthritis.

How does Placebo to tocilizumab work?

Tocilizumab is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, inhibiting the pro-inflammatory IL-6 signaling pathway.

What is Placebo to tocilizumab used for?

Placebo to tocilizumab is indicated for Rheumatoid arthritis (moderate to severe), Giant cell arteritis, Polyarticular juvenile idiopathic arthritis, Systemic sclerosis-associated interstitial lung disease, Cytokine release syndrome (CAR-T cell induced).

Who makes Placebo to tocilizumab?

Placebo to tocilizumab is developed and marketed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).

What drug class is Placebo to tocilizumab in?

Placebo to tocilizumab belongs to the IL-6 receptor antagonist class. See all IL-6 receptor antagonist drugs at /class/il-6-receptor-antagonist.

What development phase is Placebo to tocilizumab in?

Placebo to tocilizumab is FDA-approved (marketed).

What are the side effects of Placebo to tocilizumab?

Common side effects of Placebo to tocilizumab include Infection (including serious infections), Upper respiratory tract infection, Elevated liver enzymes (ALT/AST), Hyperlipidemia, Neutropenia, Gastrointestinal perforation.

What does Placebo to tocilizumab target?

Placebo to tocilizumab targets IL-6 receptor (IL-6R) and is a IL-6 receptor antagonist.

Related